{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:22:46Z","timestamp":1789039366616,"version":"build-2803163510"},"reference-count":199,"publisher":"American Association for the Advancement of Science (AAAS)","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473363"],"award-info":[{"award-number":["82473363"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272851"],"award-info":[{"award-number":["82272851"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020771","name":"Young Scientists Fund of the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["22307043"],"award-info":[{"award-number":["22307043"]}],"id":[{"id":"10.13039\/501100020771","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["2662024JC005"],"award-info":[{"award-number":["2662024JC005"]}]},{"DOI":"10.13039\/501100002858","name":"the China postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2023M731223"],"award-info":[{"award-number":["2023M731223"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"the China postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2023T160253"],"award-info":[{"award-number":["2023T160253"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["spj.science.org"],"crossmark-restriction":true},"short-container-title":["Research"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Aging is characterized by a gradual decline in the functionality of all the organs and tissues, leading to various diseases. As the global population ages, the urgency to develop effective anti-aging strategies becomes increasingly critical due to the growing severity of associated health problems. Immunotherapy offers novel and promising approaches to combat aging by utilizing approaches including vaccines, antibodies, and cytokines to target specific aging-related molecules and pathways. In this review, we summarize the recent advancements of immunotherapies to eliminate senescence cells and senescence-associated secretory phenotypes (SASPs). Next, we describe immunotherapies against age-related diseases containing neurodegenerative diseases, vascular pathologies, type 2 diabetes (T2D), arthritis, osteoporosis, chronic obstructive pulmonary disease (COPD), fibrosis, skin aging, and cancer, detailing the targets, corresponding manipulations, and clinical trials. Related problems including immunosenescence, serious adverse effects, the duality of function of senescent cells and SASPs, and inherent problems of immunotherapy are also discussed, suggesting directions for improvement. In addition to recent development and challenges in the field, we describe a blueprint of personalized aging immunotherapy by multi-omics, Big Data, artificial intelligence (AI), and nanobots in the future, aiming to inspire the development of novel strategies for healthy aging.<\/jats:p>","DOI":"10.34133\/research.0866","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T11:59:37Z","timestamp":1755172777000},"update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Immunotherapies for Aging and Age-Related Diseases: Advances, Pitfalls, and Prospects"],"prefix":"10.34133","volume":"8","author":[{"given":"Muyang","family":"Yang","sequence":"first","affiliation":[{"name":"NHC Key Laboratory of Tropical Disease Control, School of Life Sciences and Medical Technology, \rHainan Medical University, Haikou, Hainan 571199, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipeng","family":"Wu","sequence":"additional","affiliation":[{"name":"College of Biomedicine and Health and College of Life Science and Technology, \rHuazhong Agricultural University, Wuhan, Hubei 430070, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institution of Pediatric Hematology &amp; Oncology, Tongji Hospital, Tongji Medical College, \rHuazhong University of Science and Technology, Wuhan, Hubei 430030, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisen","family":"Lu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Tropical Disease Control, School of Life Sciences and Medical Technology, \rHainan Medical University, Haikou, Hainan 571199, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqiang","family":"Deng","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Tropical Disease Control, School of Life Sciences and Medical Technology, \rHainan Medical University, Haikou, Hainan 571199, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianfeng","family":"Xia","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Tropical Disease Control, School of Life Sciences and Medical Technology, \rHainan Medical University, Haikou, Hainan 571199, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan F.","family":"Lovell","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, University at Buffalo, \rState University of New York, Buffalo, NY 14260, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Shi","sequence":"additional","affiliation":[{"name":"College of Biomedicine and Health and College of Life Science and Technology, \rHuazhong Agricultural University, Wuhan, Hubei 430070, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4398-9539","authenticated-orcid":true,"given":"Honglin","family":"Jin","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Tropical Disease Control, School of Life Sciences and Medical Technology, \rHainan Medical University, Haikou, Hainan 571199, China."},{"name":"College of Biomedicine and Health and College of Life Science and Technology, \rHuazhong Agricultural University, Wuhan, Hubei 430070, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.11.001"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glu057"},{"issue":"3","key":"e_1_3_2_4_2","article-title":"Cellular senescence and the host immune system in aging and age-related disorders","volume":"46","author":"Giannoula Y","year":"2023","unstructured":"Giannoula Y, Kroemer G, Pietrocola F. Cellular senescence and the host immune system in aging and age-related disorders. Biom J. 2023;46(3): Article 100581.","journal-title":"Biom J"},{"issue":"18","key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1056\/NEJMp1912298","article-title":"Enabling healthful aging for all\u2014The National Academy of Medicine Grand Challenge in Healthy Longevity","volume":"381","author":"Dzau VJ","year":"2019","unstructured":"Dzau VJ, Inouye SK, Rowe JW, Finkelman E, Yamada T. Enabling healthful aging for all\u2014The National Academy of Medicine Grand Challenge in Healthy Longevity. N Engl J Med. 2019;381(18):1699\u20131701.","journal-title":"N Engl J Med"},{"issue":"2","key":"e_1_3_2_6_2","doi-asserted-by":"crossref","DOI":"10.1111\/acel.14038","article-title":"Calorie restriction reduces biomarkers of cellular senescence in humans","volume":"23","author":"Aversa Z","year":"2023","unstructured":"Aversa Z, White TA, Heeren AA, Hulshizer CA, Saul D, Zhang X, Molina AJA, Redman LM, Martin CK, Racette SB, et al. Calorie restriction reduces biomarkers of cellular senescence in humans. Aging Cell. 2023;23(2): Article e14038.","journal-title":"Aging Cell"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.122.000622"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2019.100977","article-title":"Anti-ageing gene therapy: Not so far away?","volume":"56","author":"Vaiserman A","year":"2019","unstructured":"Vaiserman A, De Falco E, Koliada A, Maslova O, Balistreri CR. Anti-ageing gene therapy: Not so far away? Ageing Res Rev. 2019;56: Article 100977.","journal-title":"Ageing Res Rev"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05388-4"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-00314-w"},{"issue":"1","key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: Molecular mechanisms and diseases","volume":"8","author":"Liu Z","year":"2023","unstructured":"Liu Z, Liang Q, Ren Y, Guo C, Ge X, Wang L, Cheng Q, Luo P, Zhang Y, Han X. Immunosenescence: Molecular mechanisms and diseases. Signal Transduct Target Ther. 2023;8(1):200.","journal-title":"Signal Transduct Target Ther"},{"issue":"24","key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.3390\/cells12242769","article-title":"Non-intrinsic, systemic mechanisms of cellular senescence","volume":"12","author":"Schwartz RE","year":"2023","unstructured":"Schwartz RE, Conboy. Non-intrinsic, systemic mechanisms of cellular senescence. Cells. 2023;12(24):2769.","journal-title":"Cells"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-021-00121-8"},{"issue":"12","key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/s43587-021-00151-2","article-title":"Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice","volume":"1","author":"Suda M","year":"2021","unstructured":"Suda M, Shimizu I, Katsuumi G, Yoshida Y, Hayashi Y, Ikegami R, Matsumoto N, Yoshida Y, Mikawa R, Katayama A, et al. Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nat Aging. 2021;1(12):1117\u20131126.","journal-title":"Nat Aging"},{"issue":"1","key":"e_1_3_2_15_2","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16347-w","article-title":"The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice","volume":"11","author":"Yoshida S","year":"2020","unstructured":"Yoshida S, Nakagami H, Hayashi H, Ikeda Y, Sun J, Tenma A, Tomioka H, Kawano T, Shimamura M, Morishita R, et al. The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. Nat Commun. 2020;11(1): Article 2482.","journal-title":"Nat Commun"},{"issue":"5","key":"e_1_3_2_16_2","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13806","article-title":"Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretory phenotype in mice","volume":"22","author":"Shrestha N","year":"2023","unstructured":"Shrestha N, Chaturvedi P, Zhu X, Dee MJ, George V, Janney C, Egan JO, Liu B, Foster M, Marsala L, et al. Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretory phenotype in mice. Aging Cell. 2023;22(5): Article e13806.","journal-title":"Aging Cell"},{"issue":"8006","key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/d41586-024-00680-x","article-title":"Anti-ageing antibodies revive the immune system","volume":"628","author":"Kasu YAT","year":"2024","unstructured":"Kasu YAT, Signer RAJ. Anti-ageing antibodies revive the immune system. Nature. 2024;628(8006):43\u201345.","journal-title":"Nature"},{"issue":"4","key":"e_1_3_2_18_2","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-022-04562-w","article-title":"Combining adoptive NK cell infusion with a dopamine-releasing peptide reduces senescent cells in aged mice","volume":"13","author":"Bai Z","year":"2022","unstructured":"Bai Z, Yang P, Yu F, Li Z, Yao Z, Martinez J, Li M, Xu H. Combining adoptive NK cell infusion with a dopamine-releasing peptide reduces senescent cells in aged mice. Cell Death Dis. 2022;13(4): Article 305.","journal-title":"Cell Death Dis"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2403-9"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07701-9"},{"issue":"2","key":"e_1_3_2_21_2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146071","article-title":"CD153\/CD30 signaling promotes age-dependent tertiary lymphoid tissue expansion and kidney injury","volume":"132","author":"Sato Y","year":"2022","unstructured":"Sato Y, Oguchi A, Fukushima Y, Masuda K, Toriu N, Taniguchi K, Yoshikawa T, Cui X, Kondo M, Hosoi T, et al. CD153\/CD30 signaling promotes age-dependent tertiary lymphoid tissue expansion and kidney injury. J Clin Invest. 2022;132(2): Article e146071.","journal-title":"J Clin Invest"},{"issue":"11","key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/s41564-018-0231-6","article-title":"Host resistance to pulmonary Mycobacterium tuberculosis infection requires CD153 expression","volume":"3","author":"Sallin MA","year":"2018","unstructured":"Sallin MA, Kauffman KD, Riou C, Du Bruyn E, Foreman TW, Sakai S, Hoft SG, Myers TG, Gardina PJ, Sher A, et al. Host resistance to pulmonary Mycobacterium tuberculosis infection requires CD153 expression. Nat Microbiol. 2018;3(11):1198\u20131205.","journal-title":"Nat Microbiol"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"674739","DOI":"10.3389\/fimmu.2021.674739","article-title":"The role of GPNMB in inflammation","volume":"12","author":"Saade M","year":"2021","unstructured":"Saade M, Araujo de Souza G, Scavone C, Kinoshita PF. The role of GPNMB in inflammation. Front Immunol. 2021;12:674739.","journal-title":"Front Immunol"},{"issue":"1","key":"e_1_3_2_24_2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-10522-3","article-title":"Glycoprotein nonmetastatic melanoma protein B regulates lysosomal integrity and lifespan of senescent cells","volume":"12","author":"Suda M","year":"2022","unstructured":"Suda M, Shimizu I, Katsuumi G, Hsiao CL, Yoshida Y, Matsumoto N, Yoshida Y, Katayama A, Wada J, Seki M, et al. Glycoprotein nonmetastatic melanoma protein B regulates lysosomal integrity and lifespan of senescent cells. Sci Rep. 2022;12(1): Article 6522.","journal-title":"Sci Rep"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Ai L. Xu A. & Xu J. Roles of PD-1\/PD-L1 pathway: Signaling cancer and beyond. In: Regulation of cancer immune checkpoints. Singapore: Springer; 2020. p 33\u201359.","DOI":"10.1007\/978-981-15-3266-5_3"},{"issue":"10","key":"e_1_3_2_26_2","doi-asserted-by":"crossref","DOI":"10.1128\/mcb.00171-22","article-title":"Upregulation of PD-L1 in senescence and aging","volume":"42","author":"Onorati A","year":"2023","unstructured":"Onorati A, Havas AP, Lin B, Rajagopal J, Sen P, Adams PD, Dou Z. Upregulation of PD-L1 in senescence and aging. Mol Cell Biol. 2023;42(10): Article e0017122.","journal-title":"Mol Cell Biol"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-024-01465-0"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030671"},{"issue":"2","key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.18632\/aging.100897","article-title":"NKG2D ligands mediate immunosurveillance of senescent cells","volume":"8","author":"Sagiv A","year":"2016","unstructured":"Sagiv A, Burton DGA, Moshayev Z, Vadai E, Wensveen F, Ben-Dor S, Golani O, Polic B, Krizhanovsky V. NKG2D ligands mediate immunosurveillance of senescent cells. Aging. 2016;8(2):328\u2013344.","journal-title":"Aging"},{"key":"e_1_3_2_30_2","article-title":"Autologous NK cells propagated and activated ex\u00a0vivo decrease senescence markers in human PBMCs","volume":"32","author":"Chelyapov N","year":"2022","unstructured":"Chelyapov N, Nguyen TT, Gonzalez R. Autologous NK cells propagated and activated ex\u00a0vivo decrease senescence markers in human PBMCs. Biochem Biophys Rep. 2022;32: Article 101380.","journal-title":"Biochem Biophys Rep"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0477-9"},{"issue":"1","key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11481-019-09851-4","article-title":"Where is dopamine and how do immune cells see it?: Dopamine-mediated immune cell function in health and disease","volume":"15","author":"Matt SM","year":"2019","unstructured":"Matt SM, Gaskill PJ. Where is dopamine and how do immune cells see it?: Dopamine-mediated immune cell function in health and disease. J Neuroimmune Pharmacol. 2019;15(1):114\u2013164.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"709","key":"e_1_3_2_33_2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add1951","article-title":"NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates","volume":"15","author":"Yang D","year":"2023","unstructured":"Yang D, Sun B, Li S, Wei W, Liu X, Cui X, Zhang X, Liu N, Yan L, Deng Y, et al. NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates. Sci Transl Med. 2023;15(709): Article eadd1951.","journal-title":"Sci Transl Med"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-023-00560-5"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07762-w"},{"issue":"1","key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.1038\/s41467-024-51978-3","article-title":"IL-4 drives exhaustion of CD8+ CART cells","volume":"15","author":"Stewart CM","year":"2024","unstructured":"Stewart CM, Siegler EL, Sakemura RL, Cox MJ, Huynh T, Kimball B, Mai L, Can I, Manriquez Roman C, Yun K, et al. IL-4 drives exhaustion of CD8+ CART cells. Nat Commun. 2024;15(1):7921.","journal-title":"Nat Commun"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0503280102"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.09.015"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003910"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07238-x"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.011"},{"issue":"2","key":"e_1_3_2_42_2","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afac328","article-title":"Inflammaging as a target for healthy ageing","volume":"52","author":"Dugan B","year":"2023","unstructured":"Dugan B, Conway J, Duggal NA. Inflammaging as a target for healthy ageing. Age Ageing. 2023;52(2): Article afac328.","journal-title":"Age Ageing"},{"issue":"5","key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.14336\/AD.2023.0222","article-title":"TGF-\u03b2 as a master regulator of aging-associated tissue fibrosis","volume":"14","author":"Ren L-L","year":"2023","unstructured":"Ren L-L, Miao H, Wang Y-N, Liu F, Li P, Zhao Y-Y. TGF-\u03b2 as a master regulator of aging-associated tissue fibrosis. Aging Dis. 2023;14(5):1633\u20131650.","journal-title":"Aging Dis"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.01.004"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155750"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02505-2"},{"issue":"24","key":"e_1_3_2_47_2","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer\u2019s disease: Causes and treatment","volume":"25","author":"Breijyeh Z","year":"2020","unstructured":"Breijyeh Z, Karaman R. Comprehensive review on Alzheimer\u2019s disease: Causes and treatment. Molecules. 2020;25(24):5789.","journal-title":"Molecules"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/22124"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(03)00294-0"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000073623.84147.A8"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-024-00597-0"},{"issue":"3","key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jalz.2013.12.003","article-title":"The MultiTEP platform\u2013based Alzheimer\u2019s disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates","volume":"10","author":"Davtyan H","year":"2014","unstructured":"Davtyan H, Ghochikyan A, Petrushina I, Hovakimyan A, Davtyan A, Cribbs DH, Agadjanyan MG. The MultiTEP platform\u2013based Alzheimer\u2019s disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates. Alzheimers Dement. 2014;10(3):271\u2013283.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"e_1_3_2_53_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13195-018-0340-8","article-title":"Safety, tolerability and immunogenicity of an active anti-A\u03b240 vaccine (ABvac40) in patients with Alzheimer\u2019s disease: A randomised, double-blind, placebo-controlled, phase I trial","volume":"10","author":"Lacosta A-M","year":"2018","unstructured":"Lacosta A-M, Pascual-Lucas M, Pesini P, Casabona D, P\u00e9rez-Grijalba V, Marcos-Campos I, Sarasa L, Canudas J, Badi H, Monle\u00f3n I, et al. Safety, tolerability and immunogenicity of an active anti-A\u03b240 vaccine (ABvac40) in patients with Alzheimer\u2019s disease: A randomised, double-blind, placebo-controlled, phase I trial. Alzheimer\u2019s Res Ther. 2018;10(1):12.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2361-07.2007"},{"issue":"1","key":"e_1_3_2_55_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40035-022-00292-3","article-title":"Immunotherapy for Alzheimer\u2019s disease: Targeting \u03b2-amyloid and beyond","volume":"11","author":"Song C","year":"2022","unstructured":"Song C, Shi J, Zhang P, Zhang Y, Xu J, Zhao L, Zhang R, Wang H, Chen H. Immunotherapy for Alzheimer\u2019s disease: Targeting \u03b2-amyloid and beyond. Transl Neurodegener. 2022;11(1):18.","journal-title":"Transl Neurodegener"},{"issue":"23","key":"e_1_3_2_56_2","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1074\/jbc.RA119.012517","article-title":"Phosphorylation of the overlooked tyrosine 310 regulates the structure, aggregation, and microtubule- and lipid-binding properties of tau","volume":"295","author":"Ait-Bouziad N","year":"2020","unstructured":"Ait-Bouziad N, Chiki A, Limorenko G, Xiao S, Eliezer D, Lashuel HA. Phosphorylation of the overlooked tyrosine 310 regulates the structure, aggregation, and microtubule- and lipid-binding properties of tau. J Biol Chem. 2020;295(23):7905\u20137922.","journal-title":"J Biol Chem"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.3233\/ADR-240089"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112990"},{"issue":"9","key":"e_1_3_2_60_2","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200785","article-title":"Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer\u2019s disease model","volume":"217","author":"Wang S","year":"2020","unstructured":"Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H, Ward M, Siddiqui O, Paul R, Gilfillan S, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer\u2019s disease model. J Exp Med. 2020;217(9): Article e20200785.","journal-title":"J Exp Med"},{"issue":"5","key":"e_1_3_2_61_2","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1007\/s12035-023-03736-7","article-title":"Neuritic plaques\u2014Gateways to understanding Alzheimer\u2019s disease","volume":"61","author":"Tsering W","year":"2023","unstructured":"Tsering W, Prokop S. Neuritic plaques\u2014Gateways to understanding Alzheimer\u2019s disease. Mol Neurobiol. 2023;61(5):2808\u20132821.","journal-title":"Mol Neurobiol"},{"issue":"3","key":"e_1_3_2_62_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","article-title":"Neuroinflammation and microglial activation in Alzheimer disease: Where do we go from here?","volume":"17","author":"Leng F","year":"2020","unstructured":"Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: Where do we go from here? Nat Rev Neurol. 2020;17(3):157\u2013172.","journal-title":"Nat Rev Neurol"},{"issue":"721","key":"e_1_3_2_63_2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk3225","article-title":"Central and peripheral innate and adaptive immunity in Parkinson\u2019s disease","volume":"15","author":"Harms AS","year":"2023","unstructured":"Harms AS, Yang Y-T, Tansey MG. Central and peripheral innate and adaptive immunity in Parkinson\u2019s disease. Sci Transl Med. 2023;15(721): Article eadk3225.","journal-title":"Sci Transl Med"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203395"},{"issue":"5","key":"e_1_3_2_65_2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Pagano G","year":"2022","unstructured":"Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay J-P, et al. Trial of prasinezumab in early-stage Parkinson\u2019s disease. N Engl J Med. 2022;387(5):421\u2013432.","journal-title":"N Engl J Med"},{"issue":"9","key":"e_1_3_2_66_2","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1038\/s41591-024-03101-8","article-title":"Target engagement and immunogenicity of an active immunotherapeutic targeting pathological \u03b1-synuclein: A phase 1 placebo-controlled trial","volume":"30","author":"Eijsvogel P","year":"2024","unstructured":"Eijsvogel P, Misra P, Concha-Marambio L, Boyd JD, Ding S, Fedor L, Hsieh Y-T, Sun YS, Vroom MM, Farris CM, et al. Target engagement and immunogenicity of an active immunotherapeutic targeting pathological \u03b1-synuclein: A phase 1 placebo-controlled trial. Nat Med. 2024;30(9):2631\u20132640.","journal-title":"Nat Med"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae061"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.061"},{"issue":"3","key":"e_1_3_2_69_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41440-018-0185-3","article-title":"The ATRQ\u03b2-001 vaccine improves cardiac function and prevents postinfarction cardiac remodeling in mice","volume":"42","author":"Pan Y","year":"2018","unstructured":"Pan Y, Zhou Z, Zhang H, Zhou Y, Li Y, Li C, Chen X, Yang S, Liao Y, Qiu Z. The ATRQ\u03b2-001 vaccine improves cardiac function and prevents postinfarction cardiac remodeling in mice. Hypertens Res. 2018;42(3):329\u2013340.","journal-title":"Hypertens Res"},{"issue":"21","key":"e_1_3_2_70_2","doi-asserted-by":"crossref","first-page":"6873","DOI":"10.3390\/jcm12216873","article-title":"The RAAS goodfellas in cardiovascular system","volume":"12","author":"Caputo I","year":"2023","unstructured":"Caputo I, Bertoldi G, Driussi G, Cacciapuoti M, Cal\u00f2 LA. The RAAS goodfellas in cardiovascular system. J Clin Med. 2023;12(21):6873.","journal-title":"J Clin Med"},{"issue":"6","key":"e_1_3_2_71_2","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1161\/HYPERTENSIONAHA.119.13700","article-title":"Vaccine targeted alpha 1D-adrenergic receptor for hypertension","volume":"74","author":"Li C","year":"2019","unstructured":"Li C, Yan X, Wu D, Zhang K, Liang X, Pan Y, Zhou Y, Chen F, Chen X, Yang S, et al. Vaccine targeted alpha 1D-adrenergic receptor for hypertension. Hypertension. 2019;74(6):1551\u20131562.","journal-title":"Hypertension"},{"issue":"20","key":"e_1_3_2_72_2","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.jacc.2019.02.067","article-title":"Immunotherapy of endothelin-1 receptor type A for pulmonary arterial hypertension","volume":"73","author":"Dai Y","year":"2019","unstructured":"Dai Y, Chen X, Song X, Chen X, Ma W, Lin J, Wu H, Hu X, Zhou Y, Zhang H, et al. Immunotherapy of endothelin-1 receptor type A for pulmonary arterial hypertension. J Am Coll Cardiol. 2019;73(20):2567\u20132580.","journal-title":"J Am Coll Cardiol"},{"key":"e_1_3_2_73_2","doi-asserted-by":"crossref","first-page":"170714","DOI":"10.1016\/j.peptides.2021.170714","article-title":"Immunoneutralization of human angiotensin-(1-12) with a monoclonal antibody in a humanized model of hypertension","volume":"149","author":"Ferrario CM","year":"2022","unstructured":"Ferrario CM, VonCannon JL, Zhang J, Figueroa JP, Wright KN, Groban L, Saha A, Meredith JW, Ahmad S. Immunoneutralization of human angiotensin-(1-12) with a monoclonal antibody in a humanized model of hypertension. Peptides. 2022;149:170714.","journal-title":"Peptides"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2009029117"},{"issue":"16","key":"e_1_3_2_75_2","doi-asserted-by":"crossref","first-page":"12911","DOI":"10.3390\/ijms241612911","article-title":"Advances in the pathogenesis and treatment of resistant hypertension","volume":"24","author":"Dybiec J","year":"2023","unstructured":"Dybiec J, Krzemi\u0144ska J, Radzioch E, Szlagor M, Wronka M, M\u0142ynarska E, Rysz J, Franczyk B. Advances in the pathogenesis and treatment of resistant hypertension. Int J Mol Sci. 2023;24(16):12911.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-024-00838-w"},{"issue":"14","key":"e_1_3_2_77_2","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2212476120","article-title":"Cholinergic regulation of vascular endothelial function by human ChAT+ T cells","volume":"120","author":"Tarnawski L","year":"2023","unstructured":"Tarnawski L, Shavva VS, Kort EJ, Zhuge Z, Nilsson I, Gallina AL, Mart\u00ednez-Enguita D, Heller Sahlgren B, Weiland M, Caravaca AS, et al. Cholinergic regulation of vascular endothelial function by human ChAT+ T cells. Proc Natl Acad Sci USA. 2023;120(14): Article e2212476120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_2_78_2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.989933","article-title":"Immune and inflammatory mechanisms of abdominal aortic aneurysm","volume":"13","author":"M\u00e1rquez-S\u00e1nchez AC","year":"2022","unstructured":"M\u00e1rquez-S\u00e1nchez AC, Koltsova EK. Immune and inflammatory mechanisms of abdominal aortic aneurysm. Front Immunol. 2022;13: Article 989933.","journal-title":"Front Immunol"},{"key":"e_1_3_2_79_2","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.644903","article-title":"AT1R regulates macrophage polarization through YAP and regulates aortic dissection incidence","volume":"12","author":"Wang X","year":"2021","unstructured":"Wang X, Zhang H, Ge Y, Cao L, He Y, Sun G, Jia S, Ma A, Liu J, Rong D, et al. AT1R regulates macrophage polarization through YAP and regulates aortic dissection incidence. Front Physiol. 2021;12: Article 644903.","journal-title":"Front Physiol"},{"issue":"1","key":"e_1_3_2_80_2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000488431","article-title":"Angiotensin II suppresses Rev-erb\u03b1 expression in THP-1 macrophages via the Ang II type 1 receptor\/liver X receptor \u03b1 pathway","volume":"46","author":"Wang S","year":"2018","unstructured":"Wang S, Gu X, Zhang Q, Zhang X, Li Y, Yao Y, Yu B, Zhang Y. Angiotensin II suppresses Rev-erb\u03b1 expression in THP-1 macrophages via the Ang II type 1 receptor\/liver X receptor \u03b1 pathway. Cell Physiol Biochem. 2018;46(1):303\u2013313.","journal-title":"Cell Physiol Biochem"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20110660"},{"issue":"1","key":"e_1_3_2_82_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41392-023-01325-7","article-title":"The mechanism and therapy of aortic aneurysms","volume":"8","author":"Gao J","year":"2023","unstructured":"Gao J, Cao H, Hu G, Wu Y, Xu Y, Cui H, Lu HS, Zheng L. The mechanism and therapy of aortic aneurysms. Signal Transduct Target Ther. 2023;8(1):55.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"e_1_3_2_83_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-022-00557-6","article-title":"Emerging principles of cytokine pharmacology and therapeutics","volume":"22","author":"Saxton RA","year":"2022","unstructured":"Saxton RA, Glassman CR, Garcia KC. Emerging principles of cytokine pharmacology and therapeutics. Nat Rev Drug Discov. 2022;22(1):21\u201337.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"e_1_3_2_84_2","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1161\/HYPERTENSIONAHA.119.14442","article-title":"Prevention of progression of aortic aneurysm by peptide vaccine against Ang II (angiotensin II) in a rat model","volume":"76","author":"Kurashiki T","year":"2020","unstructured":"Kurashiki T, Miyake T, Nakagami H, Nishimura M, Morishita R. Prevention of progression of aortic aneurysm by peptide vaccine against Ang II (angiotensin II) in a rat model. Hypertension. 2020;76(6):1879\u20131888.","journal-title":"Hypertension"},{"issue":"18","key":"e_1_3_2_85_2","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012341","article-title":"ATRQ\u03b2-001 vaccine prevents experimental abdominal aortic aneurysms","volume":"8","author":"Zhang H","year":"2019","unstructured":"Zhang H, Liao M, Cao M, Qiu Z, Yan X, Zhou Y, Wu H, Wang Y, Zheng J, Ding J, et al. ATRQ\u03b2-001 vaccine prevents experimental abdominal aortic aneurysms. J Am Heart Assoc. 2019;8(18): Article e012341.","journal-title":"J Am Heart Assoc"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03392-8"},{"issue":"7","key":"e_1_3_2_87_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199408183310701","article-title":"The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina","volume":"331","author":"Liuzzo G","year":"1994","unstructured":"Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331(7):417\u2013424.","journal-title":"N Engl J Med"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-021-00668-4"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2021.06.912"},{"issue":"17","key":"e_1_3_2_90_2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710135","article-title":"Factors and pathways modulating endothelial cell senescence in vascular aging","volume":"23","author":"Hwang HJ","year":"2022","unstructured":"Hwang HJ, Kim N, Herman AB, Gorospe M, Lee J-S. Factors and pathways modulating endothelial cell senescence in vascular aging. Int J Mol Sci. 2022;23(17): Article 10135.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"e_1_3_2_91_2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015160","article-title":"New dawn for atherosclerosis: Vascular endothelial cell senescence and death","volume":"24","author":"Bu L-L","year":"2023","unstructured":"Bu L-L, Yuan H-H, Xie L-L, Guo M-H, Liao D-F, Zheng X-L. New dawn for atherosclerosis: Vascular endothelial cell senescence and death. Int J Mol Sci. 2023;24(20): Article 15160.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113059"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.18.12.1972"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121581"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115770"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914"},{"issue":"5","key":"e_1_3_2_97_2","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014941","article-title":"Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment\u2013elevation myocardial infarction","volume":"9","author":"Abbate A","year":"2020","unstructured":"Abbate A, Trankle CR, Buckley LF, Lipinski MJ, Appleton D, Kadariya D, Canada JM, Carbone S, Roberts CS, Abouzaki N, et al. Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment\u2013elevation myocardial infarction. J Am Heart Assoc. 2020;9(5): Article e014941.","journal-title":"J Am Heart Assoc"},{"issue":"15","key":"e_1_3_2_98_2","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","article-title":"Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction","volume":"77","author":"Broch K","year":"2021","unstructured":"Broch K, Anstensrud AK, Woxholt S, Sharma K, T\u00f8llefsen IM, Bendz B, Aakhus S, Ueland T, Amundsen BH, Dam\u00e5s JK, et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77(15):1845\u20131855.","journal-title":"J Am Coll Cardiol"},{"issue":"10289","key":"e_1_3_2_99_2","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker PM","year":"2021","unstructured":"Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, Lo L, Kling D, Pergola P, Raj D, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060\u20132069.","journal-title":"Lancet"},{"key":"e_1_3_2_100_2","doi-asserted-by":"crossref","first-page":"9845459","DOI":"10.34133\/2022\/9845459","article-title":"Platelet membrane-coated nanocarriers targeting plaques to deliver anti-CD47 antibody for atherosclerotic therapy","volume":"2022","author":"Chen L","year":"2022","unstructured":"Chen L, Zhou Z, Hu C, Maitz MF, Yang L, Luo R, Wang Y. Platelet membrane-coated nanocarriers targeting plaques to deliver anti-CD47 antibody for atherosclerotic therapy. Research. 2022;2022:9845459.","journal-title":"Research"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30058-2"},{"issue":"18","key":"e_1_3_2_102_2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186842","article-title":"Pharmacogenetics of type 2 diabetes\u2014Progress and prospects","volume":"21","author":"Nasykhova YA","year":"2020","unstructured":"Nasykhova YA, Tonyan ZN, Mikhailova AA, Danilova MM, Glotov AS. Pharmacogenetics of type 2 diabetes\u2014Progress and prospects. Int J Mol Sci. 2020;21(18): Article 6842.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"e_1_3_2_103_2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon CF","year":"2020","unstructured":"Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(11):642\u2013653.","journal-title":"Nat Rev Endocrinol"},{"issue":"15","key":"e_1_3_2_104_2","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1101\/gad.302570.117","article-title":"Identification of senescent cell surface targetable protein DPP4","volume":"31","author":"Kim KM","year":"2017","unstructured":"Kim KM, Noh JH, Bodogai M, Martindale JL, Yang X, Indig FE, Basu SK, Ohnuma K, Morimoto C, Johnson PF, et al. Identification of senescent cell surface targetable protein DPP4. Genes Dev. 2017;31(15):1529\u20131534.","journal-title":"Genes Dev"},{"issue":"13","key":"e_1_3_2_105_2","doi-asserted-by":"crossref","first-page":"E1256","DOI":"10.1073\/pnas.1322009111","article-title":"Therapeutic vaccine against DPP4 improves glucose metabolism in mice","volume":"111","author":"Pang Z","year":"2014","unstructured":"Pang Z, Nakagami H, Osako MK, Koriyama H, Nakagami F, Tomioka H, Shimamura M, Kurinami H, Takami Y, Morishita R, et al. Therapeutic vaccine against DPP4 improves glucose metabolism in mice. Proc Natl Acad Sci USA. 2014;111(13):E1256\u2013E1263.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"e_1_3_2_106_2","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.3390\/life13112213","article-title":"Adiponectin: A promising target for the treatment of diabetes and its complications","volume":"13","author":"Begum M","year":"2023","unstructured":"Begum M, Choubey M, Tirumalasetty MB, Arbee S, Mohib MM, Wahiduzzaman M, Mamun MA, Uddin MB, Mohiuddin MS. Adiponectin: A promising target for the treatment of diabetes and its complications. Life. 2023;13(11):2213.","journal-title":"Life"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2015.06.004"},{"issue":"45","key":"e_1_3_2_108_2","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg4216","article-title":"A monoclonal antibody activating AdipoR for type 2 diabetes and nonalcoholic steatohepatitis","volume":"9","author":"Asahara N","year":"2023","unstructured":"Asahara N, Okada-Iwabu M, Iwabu M, Wada K, Oka K, Yamauchi T, Kadowaki T. A monoclonal antibody activating AdipoR for type 2 diabetes and nonalcoholic steatohepatitis. Sci Adv. 2023;9(45): Article eadg4216.","journal-title":"Sci Adv"},{"issue":"4","key":"e_1_3_2_109_2","first-page":"114","article-title":"Can monoclonal antibodies against CGRP offer new treatment options for type 2 diabetes?","volume":"2","author":"Riera CE","year":"2020","unstructured":"Riera CE. Can monoclonal antibodies against CGRP offer new treatment options for type 2 diabetes? J Diabetes Clin Res. 2020;2(4):114\u2013118.","journal-title":"J Diabetes Clin Res"},{"issue":"1","key":"e_1_3_2_110_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262568","article-title":"Effect of prorenin peptide vaccine on the early phase of diabetic retinopathy in a murine model of type 2 diabetes","volume":"17","author":"Lewin AS","year":"2022","unstructured":"Lewin AS, Yokota H, Hayashi H, Hanaguri J, Yamagami S, Kushiyama A, Nakagami H, Nagaoka T. Effect of prorenin peptide vaccine on the early phase of diabetic retinopathy in a murine model of type 2 diabetes. PLOS ONE. 2022;17(1): Article e0262568.","journal-title":"PLOS ONE"},{"issue":"6","key":"e_1_3_2_111_2","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.ajpath.2011.02.036","article-title":"\u03b2-Cell loss and \u03b2-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition","volume":"178","author":"Jurgens CA","year":"2011","unstructured":"Jurgens CA, Toukatly MN, Fligner CL, Udayasankar J, Subramanian SL, Zraika S, Aston-Mourney K, Carr DB, Westermark P, Westermark GT, et al. \u03b2-Cell loss and \u03b2-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol. 2011;178(6):2632\u20132640.","journal-title":"Am J Pathol"},{"issue":"1","key":"e_1_3_2_112_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00125-021-05569-2","article-title":"IAPP-induced beta cell stress recapitulates the islet transcriptome in type 2 diabetes","volume":"65","author":"Blencowe M","year":"2021","unstructured":"Blencowe M, Furterer A, Wang Q, Gao F, Rosenberger M, Pei L, Nomoto H, Mawla AM, Huising MO, Coppola G, et al. IAPP-induced beta cell stress recapitulates the islet transcriptome in type 2 diabetes. Diabetologia. 2021;65(1):173\u2013187.","journal-title":"Diabetologia"},{"issue":"1","key":"e_1_3_2_113_2","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8010116","article-title":"Vaccination against amyloidogenic aggregates in pancreatic islets prevents development of type 2 diabetes mellitus","volume":"8","author":"Roesti ES","year":"2020","unstructured":"Roesti ES, Boyle CN, Zeman DT, Sande-Melon M, Storni F, Cabral-Miranda G, Knuth A, Lutz TA, Vogel M, Bachmann MF. Vaccination against amyloidogenic aggregates in pancreatic islets prevents development of type 2 diabetes mellitus. Vaccine. 2020;8(1): Article 116.","journal-title":"Vaccine"},{"issue":"11","key":"e_1_3_2_114_2","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/vaccines9111316","article-title":"Anti-IAPP monoclonal antibody improves clinical symptoms in a mouse model of type 2 diabetes","volume":"9","author":"Vogt A-CS","year":"2021","unstructured":"Vogt A-CS, Roesti ES, Mohsen MO, Leonchiks A, Vogel M, Bachmann MF. Anti-IAPP monoclonal antibody improves clinical symptoms in a mouse model of type 2 diabetes. Vaccine. 2021;9(11):1316.","journal-title":"Vaccine"},{"issue":"34","key":"e_1_3_2_115_2","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202202342","article-title":"Human islet amyloid polypeptide (hIAPP) protofibril-specific antibodies for detection and treatment of type 2 diabetes","volume":"9","author":"Bortoletto AS","year":"2022","unstructured":"Bortoletto AS, Graham WV, Trout G, Bonito-Oliva A, Kazmi MA, Gong J, Weyburne E, Houser BL, Sakmar TP, Parchem RJ. Human islet amyloid polypeptide (hIAPP) protofibril-specific antibodies for detection and treatment of type 2 diabetes. Adv Sci. 2022;9(34): Article e2202342.","journal-title":"Adv Sci"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00886-5"},{"issue":"8","key":"e_1_3_2_117_2","article-title":"Safety and efficacy of canakinumab for the prevention and control of type 2 diabetes mellitus and its complications: A systematic review","volume":"16","author":"Lanka N","year":"2024","unstructured":"Lanka N, Acharya P, Virani S, Afreen S, Perthiani A, Sangster E, Arcia Franchini AP. Safety and efficacy of canakinumab for the prevention and control of type 2 diabetes mellitus and its complications: A systematic review. Cureus. 2024;16(8): Article e67065.","journal-title":"Cureus"},{"issue":"5","key":"e_1_3_2_118_2","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/mt.2015.227","article-title":"Development of an interleukin-1\u03b2 vaccine in patients with type 2 diabetes","volume":"24","author":"Cavelti-Weder C","year":"2016","unstructured":"Cavelti-Weder C, Timper K, Seelig E, Keller C, Osranek M, L\u00e4ssing U, Spohn G, Maurer P, M\u00fcller P, Jennings GT, et al. Development of an interleukin-1\u03b2 vaccine in patients with type 2 diabetes. Mol Ther. 2016;24(5):1003\u20131012.","journal-title":"Mol Ther"},{"issue":"1","key":"e_1_3_2_119_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/mabs.2.1.10328","article-title":"Canakinumab","volume":"2","author":"Dhimolea E","year":"2014","unstructured":"Dhimolea E. Canakinumab. MAbs. 2014;2(1):3\u201313.","journal-title":"MAbs"},{"issue":"10","key":"e_1_3_2_120_2","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","article-title":"Global, regional, and national burden of rheumatoid arthritis, 1990\u20132020, and projections to 2050: A systematic analysis of the global burden of disease study 2021","volume":"5","author":"Black RJ","year":"2023","unstructured":"Black RJ, Cross M, Haile LM, Culbreth GT, Steinmetz JD, Hagins H, Kopec JA, Brooks PM, Woolf AD, Ong KL, et al. Global, regional, and national burden of rheumatoid arthritis, 1990\u20132020, and projections to 2050: A systematic analysis of the global burden of disease study 2021. Lancet Rheumatol. 2023;5(10):e594\u2013e610.","journal-title":"Lancet Rheumatol"},{"issue":"10416","key":"e_1_3_2_121_2","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo A","year":"2023","unstructured":"Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023;402(10416):2019\u20132033.","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_2_122_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: A systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano A","year":"2023","unstructured":"Sepriano A, Kerschbaumer A, Bergstra SA, Smolen JS, van der Heijde D, Caporali R, Edwards CJ, Verschueren P, de Souza S, Pope J, et al. Safety of synthetic and biological DMARDs: A systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023;82(1):107\u2013118.","journal-title":"Ann Rheum Dis"},{"issue":"10429","key":"e_1_3_2_123_2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","article-title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): A randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial","volume":"403","author":"Cope AP","year":"2024","unstructured":"Cope AP, Jasenecova M, Vasconcelos JC, Filer A, Raza K, Qureshi S, D\u2019Agostino MA, McInnes IB, Isaacs JD, Pratt AG, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): A randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. 2024;403(10429):838\u2013849.","journal-title":"Lancet"},{"key":"e_1_3_2_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.04.034"},{"issue":"18","key":"e_1_3_2_125_2","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1016\/j.scib.2024.02.042","article-title":"A citrullinated antigenic vaccine in treatment of autoimmune arthritis","volume":"69","author":"Jin X","year":"2024","unstructured":"Jin X, Dong T, Wang Q, Xie Y, Fang X, Wei C, Liu S, Zheng X, Wang P, Zhu D, et al. A citrullinated antigenic vaccine in treatment of autoimmune arthritis. Sci Bull. 2024;69(18):2920\u20132929.","journal-title":"Sci Bull"},{"issue":"290","key":"e_1_3_2_126_2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype\u2013positive rheumatoid arthritis patients","volume":"7","author":"Benham H","year":"2015","unstructured":"Benham H, Nel HJ, Law SC, Mehdi AM, Street S, Ramnoruth N, Pahau H, Lee BT, Ng J, Brunck ME, et al. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype\u2013positive rheumatoid arthritis patients. Sci Transl Med. 2015;7(290): Article 290ra87.","journal-title":"Sci Transl Med"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0071"},{"key":"e_1_3_2_128_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217844"},{"issue":"21","key":"e_1_3_2_129_2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111592","article-title":"Mesenchymal stem cell-based therapy for rheumatoid arthritis","volume":"22","author":"Sarsenova M","year":"2021","unstructured":"Sarsenova M, Issabekova A, Abisheva S, Rutskaya-Moroshan K, Ogay V, Saparov A. Mesenchymal stem cell-based therapy for rheumatoid arthritis. Int J Mol Sci. 2021;22(21): Article 11592.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_2_130_2","doi-asserted-by":"crossref","DOI":"10.34133\/research.0220","article-title":"Current immunotherapy strategies for rheumatoid arthritis: The immunoengineering and delivery systems","volume":"6","author":"Zhang C","year":"2023","unstructured":"Zhang C, Ma P, Qin A, Wang L, Dai K, Liu Y, Zhao J, Lu Z. Current immunotherapy strategies for rheumatoid arthritis: The immunoengineering and delivery systems. Research. 2023;6: Article 0220.","journal-title":"Research"},{"issue":"1","key":"e_1_3_2_131_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41392-023-01330-w","article-title":"Osteoarthritis: Pathogenic signaling pathways and therapeutic targets","volume":"8","author":"Yao Q","year":"2023","unstructured":"Yao Q, Wu X, Tao C, Gong W, Chen M, Qu M, Zhong Y, He T, Chen S, Xiao G. Osteoarthritis: Pathogenic signaling pathways and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):56.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"e_1_3_2_132_2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-022-02859-x","article-title":"Senescence in osteoarthritis: From mechanism to potential treatment","volume":"24","author":"Liu Y","year":"2022","unstructured":"Liu Y, Zhang Z, Li T, Xu H, Zhang H. Senescence in osteoarthritis: From mechanism to potential treatment. Arthritis Res Ther. 2022;24(1):174.","journal-title":"Arthritis Res Ther"},{"issue":"17","key":"e_1_3_2_133_2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179208","article-title":"Cytokines and chemokines involved in osteoarthritis pathogenesis","volume":"22","author":"Molnar V","year":"2021","unstructured":"Molnar V, Matisic V, Kodvanj I, Bjelica R, Jelec Z, Hudetz D, Rod E, Cukelj F, Vrdoljak T, Vidovic D, et al. Cytokines and chemokines involved in osteoarthritis pathogenesis. Int J Mol Sci. 2021;22(17): Article 9208.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_2_134_2","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.2147\/JIR.S474879","article-title":"Role of IL-1 family cytokines IL-36, IL-37, IL-38 in osteoarthritis and rheumatoid arthritis: A comprehensive review","volume":"17","author":"Xu Y","year":"2024","unstructured":"Xu Y, Wang J-Y, Zou Y, Ma X-W, Meng T. Role of IL-1 family cytokines IL-36, IL-37, IL-38 in osteoarthritis and rheumatoid arthritis: A comprehensive review. J Inflamm Res. 2024;17:4001\u20134016.","journal-title":"J Inflamm Res"},{"key":"e_1_3_2_135_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22171"},{"issue":"2","key":"e_1_3_2_136_2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40122-021-00260-1","article-title":"Management of osteoarthritis: Expert opinion on NSAIDs","volume":"10","author":"Magni A","year":"2021","unstructured":"Magni A, Agostoni P, Bonezzi C, Massazza G, Mene P, Savarino V, Fornasari D. Management of osteoarthritis: Expert opinion on NSAIDs. Pain Ther. 2021;10(2):783\u2013808.","journal-title":"Pain Ther"},{"issue":"1","key":"e_1_3_2_137_2","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12712","article-title":"Immune modulation by mesenchymal stem cells","volume":"53","author":"Jiang W","year":"2019","unstructured":"Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif. 2019;53(1): Article e12712.","journal-title":"Cell Prolif"},{"key":"e_1_3_2_138_2","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.575057","article-title":"Immunomodulation of MSCs and MSC-derived extracellular vesicles in osteoarthritis","volume":"8","author":"Zhao X","year":"2020","unstructured":"Zhao X, Zhao Y, Sun X, Xing Y, Wang X, Yang Q. Immunomodulation of MSCs and MSC-derived extracellular vesicles in osteoarthritis. Front Bioeng Biotechnol. 2020;8: Article 575057.","journal-title":"Front Bioeng Biotechnol"},{"issue":"3","key":"e_1_3_2_139_2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/sctm.18-0053","article-title":"Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: Repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I\/II trial","volume":"8","author":"Matas J","year":"2019","unstructured":"Matas J, Orrego M, Amenabar D, Infante C, Tapia-Limonchi R, Cadiz MI, Alcayaga-Miranda F, Gonz\u00e1lez PL, Muse E, Khoury M, et al. Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: Repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I\/II trial. Stem Cells Transl Med. 2019;8(3):215\u2013224.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"e_1_3_2_140_2","doi-asserted-by":"crossref","DOI":"10.1186\/s13018-017-0689-6","article-title":"Intra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: A phase I\/II study","volume":"12","author":"Al-Najar M","year":"2017","unstructured":"Al-Najar M, Khalil H, Al-Ajlouni J, Al-Antary E, Hamdan M, Rahmeh R, Alhattab D, Samara O, Yasin M, Abdullah AA, et al. Intra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: A phase I\/II study. J Orthop Surg Res. 2017;12(1): Article 190.","journal-title":"J Orthop Surg Res"},{"issue":"16","key":"e_1_3_2_141_2","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade4645","article-title":"The synovial environment steers cartilage deterioration and regeneration","volume":"9","author":"Bolander J","year":"2023","unstructured":"Bolander J, Moviglia Brandolina MT, Poehling G, Jochl O, Parsons E, Vaughan W, Moviglia G, Atala A. The synovial environment steers cartilage deterioration and regeneration. Sci Adv. 2023;9(16): Article eade4645.","journal-title":"Sci Adv"},{"key":"e_1_3_2_142_2","article-title":"Epigenetic regulations of cellular senescence in osteoporosis","volume":"99","author":"Huo S","year":"2024","unstructured":"Huo S, Tang X, Chen W, Gan D, Guo H, Yao Q, Liao R, Huang T, Wu J, Yang J, et al. Epigenetic regulations of cellular senescence in osteoporosis. Ageing Res Rev. 2024;99.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"e_1_3_2_143_2","article-title":"Insights and implications of sexual dimorphism in osteoporosis","volume":"12","author":"Zhang Y-Y","year":"2024","unstructured":"Zhang Y-Y, Xie N, Sun X-D, Nice EC, Liou Y-C, Huang C, Zhu H, Shen Z. Insights and implications of sexual dimorphism in osteoporosis. Bone Res. 2024;12(1): Article 102235.","journal-title":"Bone Res"},{"issue":"1","key":"e_1_3_2_144_2","doi-asserted-by":"crossref","DOI":"10.1038\/s41413-024-00362-4","article-title":"Mapping RANKL- and OPG-expressing cells in bone tissue: The bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect","volume":"12","author":"El-Masri BM","year":"2024","unstructured":"El-Masri BM, Andreasen CM, Laursen KS, Kofod VB, Dahl XG, Nielsen MH, Thomsen JS, Br\u00fcel A, S\u00f8rensen MS, Hansen LJ, et al. Mapping RANKL- and OPG-expressing cells in bone tissue: The bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect. Bone Res. 2024;12(1): Article 62.","journal-title":"Bone Res"},{"issue":"10329","key":"e_1_3_2_145_2","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","article-title":"Drug therapy for osteoporosis in older adults","volume":"399","author":"Reid IR","year":"2022","unstructured":"Reid IR, Billington EO. Drug therapy for osteoporosis in older adults. Lancet. 2022;399(10329):1080\u20131092.","journal-title":"Lancet"},{"issue":"14","key":"e_1_3_2_146_2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s40265-021-01587-x","article-title":"Bone mineral density loss and fracture risk after discontinuation of anti-osteoporotic drug treatment: A narrative review","volume":"81","author":"Elbers LPB","year":"2021","unstructured":"Elbers LPB, Raterman HG, Lems WF. Bone mineral density loss and fracture risk after discontinuation of anti-osteoporotic drug treatment: A narrative review. Drugs. 2021;81(14):1645\u20131655.","journal-title":"Drugs"},{"issue":"1","key":"e_1_3_2_147_2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41413-023-00274-9","article-title":"Reversal of the diabetic bone signature with anabolic therapies in mice","volume":"11","author":"Marino S","year":"2023","unstructured":"Marino S, Akel N, Li S, Cregor M, Jones M, Perez B, Troncoso G, Meeks J, Stewart S, Sato AY, et al. Reversal of the diabetic bone signature with anabolic therapies in mice. Bone Res. 2023;11(1):32.","journal-title":"Bone Res"},{"issue":"549","key":"e_1_3_2_148_2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay6570","article-title":"Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics","volume":"12","author":"Bovijn J","year":"2020","unstructured":"Bovijn J, Krebs K, Chen C-Y, Boxall R, Censin JC, Ferreira T, Pulit SL, Glastonbury CA, Laber S, Millwood IY, et al. Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Sci Transl Med. 2020;12(549): Article eaay6570.","journal-title":"Sci Transl Med"},{"issue":"6","key":"e_1_3_2_149_2","doi-asserted-by":"crossref","DOI":"10.3390\/medicina58060817","article-title":"Senescence: Pathogenic driver in chronic obstructive pulmonary disease","volume":"58","author":"Rivas M","year":"2022","unstructured":"Rivas M, Gupta G, Costanzo L, Ahmed H, Wyman AE, Geraghty P. Senescence: Pathogenic driver in chronic obstructive pulmonary disease. Medicina. 2022;58(6): Article 817.","journal-title":"Medicina"},{"key":"e_1_3_2_150_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186924"},{"key":"e_1_3_2_151_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00233-1"},{"issue":"9","key":"e_1_3_2_152_2","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1007\/s12325-022-02231-0","article-title":"Fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) triple therapy compared with other therapies for the treatment of COPD: A network meta-analysis","volume":"39","author":"Ismaila AS","year":"2022","unstructured":"Ismaila AS, Haeussler K, Czira A, Youn J-H, Malmen\u00e4s M, Risebrough NA, Agarwal J, Nassim M, Sharma R, Compton C, et al. Fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) triple therapy compared with other therapies for the treatment of COPD: A network meta-analysis. Adv Ther. 2022;39(9):3957\u20133978.","journal-title":"Adv Ther"},{"key":"e_1_3_2_153_2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2147\/COPD.S28250","article-title":"Geroprotectors as a novel therapeutic strategy for COPD, an accelerating aging disease","volume":"7","author":"Ito K","year":"2012","unstructured":"Ito K, Colley & Mercado. Geroprotectors as a novel therapeutic strategy for COPD, an accelerating aging disease. Int J Chron Obstruct Pulmon Dis. 2012;7:641\u2013652.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"e_1_3_2_154_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.18632\/aging.100273","article-title":"If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice","volume":"3","author":"Anisimov VN","year":"2011","unstructured":"Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Kovalenko IG, et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging. 2011;3(2):148\u2013157.","journal-title":"Aging"},{"issue":"1","key":"e_1_3_2_155_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.chest.2025.01.029","article-title":"Effect of dupilumab on health-related quality of life and respiratory symptoms in patients with COPD and type 2 inflammation","volume":"168","author":"Bhatt SP","year":"2025","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, et al. Effect of dupilumab on health-related quality of life and respiratory symptoms in patients with COPD and type 2 inflammation. Chest. 2025;168(1):56\u201366.","journal-title":"Chest"},{"issue":"3","key":"e_1_3_2_156_2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S2213-2600(24)00409-0","article-title":"Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: A pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials","volume":"13","author":"Bhatt SP","year":"2025","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, et al. Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: A pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2025;13(3):234\u2013243.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"e_1_3_2_157_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): A randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh D","year":"2025","unstructured":"Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, Papi A, Pavord ID, Molfino NA, Almqvist G, et al. Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): A randomised, placebo-controlled, phase 2a trial. Lancet Respir Med. 2025;13(1):47\u201358.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"e_1_3_2_158_2","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202308229","article-title":"DNA adjuvant hydrogel-optimized enzymatic cascade reaction for tumor chemodynamic-immunotherapy","volume":"11","author":"Zhao Y","year":"2024","unstructured":"Zhao Y, Du J, Xu Z, Wang L, Ma L, Sun L. DNA adjuvant hydrogel-optimized enzymatic cascade reaction for tumor chemodynamic-immunotherapy. Adv Sci. 2024;11(10): Article e2308229.","journal-title":"Adv Sci"},{"issue":"17","key":"e_1_3_2_159_2","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba FC","year":"2025","unstructured":"Sciurba FC, Criner GJ, Christenson SA, Martinez FJ, Papi A, Roche N, Bourbeau J, Korn S, Bafadhel M, Han MK, et al. Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype. N Engl J Med. 2025;392(17):1710\u20131720.","journal-title":"N Engl J Med"},{"issue":"44","key":"e_1_3_2_160_2","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202405318","article-title":"Targeting immunoproteasome in polarized macrophages ameliorates experimental emphysema via activating NRF1\/2-P62 axis and suppressing IRF4 transcription","volume":"11","author":"Guo B","year":"2024","unstructured":"Guo B, Shi X, Jiang Q, Pan Y, Yang Y, Liu Y, Chen S, Zhu W, Ren L, Liang R, et al. Targeting immunoproteasome in polarized macrophages ameliorates experimental emphysema via activating NRF1\/2-P62 axis and suppressing IRF4 transcription. Adv Sci. 2024;11(44): Article e2405318.","journal-title":"Adv Sci"},{"key":"e_1_3_2_161_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2938-9"},{"key":"e_1_3_2_162_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2024.05.012"},{"key":"e_1_3_2_163_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.5680"},{"key":"e_1_3_2_164_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1546-z"},{"key":"e_1_3_2_165_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0594"},{"key":"e_1_3_2_166_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2022.08.012"},{"key":"e_1_3_2_167_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00591-5"},{"issue":"23","key":"e_1_3_2_168_2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312641","article-title":"Skin aging, cellular senescence and natural polyphenols","volume":"22","author":"Csekes E","year":"2021","unstructured":"Csekes E, Ra\u010dkov\u00e1 L. Skin aging, cellular senescence and natural polyphenols. Int J Mol Sci. 2021;22(23): Article 12641.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"e_1_3_2_169_2","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.3390\/ijms25074101","article-title":"Research progress in skin aging and immunity","volume":"25","author":"He X","year":"2024","unstructured":"He X, Gao X, Xie W. Research progress in skin aging and immunity. Int J Mol Sci. 2024;25(7):4101.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_2_170_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2021.12.003"},{"key":"e_1_3_2_171_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-023-00431-z"},{"key":"e_1_3_2_172_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.02.033"},{"issue":"5","key":"e_1_3_2_173_2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nrc3497","article-title":"How ageing processes influence cancer","volume":"13","author":"Magalh\u00e3es JP","year":"2013","unstructured":"de Magalh\u00e3es JP. How ageing processes influence cancer. Nat Rev Cancer. 2013;13(5):357\u2013365.","journal-title":"Nat Rev Cancer"},{"key":"e_1_3_2_174_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2024.03.002"},{"key":"e_1_3_2_175_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.05.026"},{"issue":"8","key":"e_1_3_2_176_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.xgen.2023.100347","article-title":"Cystatin C is glucocorticoid responsive, directs recruitment of Trem2+ macrophages, and predicts failure of cancer immunotherapy","volume":"3","author":"Kleeman SO","year":"2023","unstructured":"Kleeman SO, Thakir TM, Demestichas B, Mourikis N, Loiero D, Ferrer M, Bankier S, Riazat-Kesh YJRA, Lee H, Chantzichristos D, et al. Cystatin C is glucocorticoid responsive, directs recruitment of Trem2+ macrophages, and predicts failure of cancer immunotherapy. Cell Genom. 2023;3(8): Article 100347.","journal-title":"Cell Genom"},{"issue":"6720","key":"e_1_3_2_177_2","article-title":"Hematopoietic aging promotes cancer by fueling IL-1\u03b1\u2013driven emergency myelopoiesis","volume":"386","author":"Park MD","year":"2024","unstructured":"Park MD, Le Berichel J, Hamon P, Wilk CM, Belabed M, Yatim N, Saffon A, Boumelha J, Falcomat\u00e0 C, Tepper A, et al. Hematopoietic aging promotes cancer by fueling IL-1\u03b1\u2013driven emergency myelopoiesis. Science. 2024;386(6720).","journal-title":"Science"},{"issue":"1","key":"e_1_3_2_178_2","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li K","year":"2021","unstructured":"Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, Shu P, Li D, Wang Y. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6(1): Article eadn0327.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_2_179_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00846-y"},{"key":"e_1_3_2_180_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01828-7"},{"issue":"11","key":"e_1_3_2_181_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103365","article-title":"Senotherapies: A novel strategy for synergistic anti-tumor therapy","volume":"27","author":"Qi X","year":"2022","unstructured":"Qi X, Jiang L, Cao J. Senotherapies: A novel strategy for synergistic anti-tumor therapy. Drug Discov Today. 2022;27(11): Article 103365.","journal-title":"Drug Discov Today"},{"key":"e_1_3_2_182_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-024-00747-4"},{"key":"e_1_3_2_183_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1338"},{"key":"e_1_3_2_184_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature17963"},{"issue":"5","key":"e_1_3_2_185_2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael Y","year":"2022","unstructured":"Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel S-E, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022;40(5):509\u2013523.e506.","journal-title":"Cancer Cell"},{"issue":"10","key":"e_1_3_2_186_2","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/jnci\/djab064","article-title":"Therapy-induced senescence: Opportunities to improve anticancer therapy","volume":"113","author":"Prasanna PG","year":"2021","unstructured":"Prasanna PG, Citrin DE, Hildesheim J, Ahmed MM, Venkatachalam S, Riscuta G, Xi D, Zheng G, , et al. Therapy-induced senescence: Opportunities to improve anticancer therapy. J Natl Cancer Inst. 2021;113(10):1285\u20131298.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"e_1_3_2_187_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009258","article-title":"Inclusion, characteristics, and reporting of older adults in FDA registration studies of immunotherapy, 2018\u20132022","volume":"12","author":"Mac Eochagain C","year":"2024","unstructured":"Mac Eochagain C, Power R, Sam C, Gonzalez-Senac NM, Walsh D, Roy M, Battisti NML. Inclusion, characteristics, and reporting of older adults in FDA registration studies of immunotherapy, 2018\u20132022. J Immunother Cancer. 2024;12(8): Article e009258.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_2_188_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-3717"},{"key":"e_1_3_2_189_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.05.002"},{"key":"e_1_3_2_190_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae339"},{"issue":"7","key":"e_1_3_2_191_2","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1093\/cvr\/cvad008","article-title":"The longevity-associated BPIFB4 gene supports cardiac function and vascularization in ageing cardiomyopathy","volume":"119","author":"Cattaneo M","year":"2023","unstructured":"Cattaneo M, Beltrami AP, Thomas AC, Spinetti G, Alvino VV, Avolio E, Veneziano C, Rolle IG, Sponga S, Sangalli E, et al. The longevity-associated BPIFB4 gene supports cardiac function and vascularization in ageing cardiomyopathy. Cardiovasc Res. 2023;119(7):1583\u20131595.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"e_1_3_2_192_2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41467-023-35952-z","article-title":"A new AMPK isoform mediates glucose-restriction induced longevity non-cell autonomously by promoting membrane fluidity","volume":"14","author":"Jeong J-H","year":"2023","unstructured":"Jeong J-H, Han J-S, Jung Y, Lee S-M, Park S-H, Park M, Shin M-G, Kim N, Kang MS, Kim S, et al. A new AMPK isoform mediates glucose-restriction induced longevity non-cell autonomously by promoting membrane fluidity. Nat Commun. 2023;14(1):288.","journal-title":"Nat Commun"},{"issue":"1","key":"e_1_3_2_193_2","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1038\/s41467-023-37729-w","article-title":"Multi-omic underpinnings of epigenetic aging and human longevity","volume":"14","author":"Mavromatis LA","year":"2023","unstructured":"Mavromatis LA, Rosoff DB, Bell AS, Jung J, Wagner J, Lohoff FW. Multi-omic underpinnings of epigenetic aging and human longevity. Nat Commun. 2023;14(1):2236.","journal-title":"Nat Commun"},{"issue":"1","key":"e_1_3_2_194_2","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-46510-6","article-title":"The chromatin factors SET-26 and HCF-1 oppose the histone deacetylase HDA-1 in longevity and gene regulation in C. elegans","volume":"15","author":"Emerson FJ","year":"2024","unstructured":"Emerson FJ, Chiu C, Lin LY, Riedel CG, Zhu M, Lee SS. The chromatin factors SET-26 and HCF-1 oppose the histone deacetylase HDA-1 in longevity and gene regulation in C. elegans. Nat Commun. 2024;15(1): Article 2320.","journal-title":"Nat Commun"},{"key":"e_1_3_2_195_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102585"},{"key":"e_1_3_2_196_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.10.019"},{"key":"e_1_3_2_197_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-023-00527-6"},{"key":"e_1_3_2_198_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.05.059"},{"issue":"8037","key":"e_1_3_2_199_2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/d41586-024-03595-9","article-title":"Five protein-design questions that still challenge AI","volume":"635","author":"Reardon S","year":"2024","unstructured":"Reardon S. Five protein-design questions that still challenge AI. Nature. 2024;635(8037):246\u2013248.","journal-title":"Nature"},{"key":"e_1_3_2_200_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31561-0"}],"container-title":["Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.34133\/research.0866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T08:00:44Z","timestamp":1757318444000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.34133\/research.0866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":199,"alternative-id":["10.34133\/research.0866"],"URL":"https:\/\/doi.org\/10.34133\/research.0866","relation":{},"ISSN":["2639-5274"],"issn-type":[{"value":"2639-5274","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2025-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"0866"}}